THALES
4.6.2024 09:01:35 CEST | Business Wire | Press release
The United Kingdom government’s Driver and Vehicle Licensing Agency (DVLA) partners with Thales to reduce the carbon footprint of its driving licences as well as tachograph and residence cards. Since 2018, Thales has cut by over one third the CO2 emissions associated with the 12 million cards it supplies to the DVLA every year, without compromising the outstanding security, durability and value-for-money provided by these products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604196678/en/
(credit: Shutterstock – Jubemo/Thales)
The DVLA is responsible for maintaining accurate records of more than 52 million drivers in Great Britain and more than 46 million vehicles across the UK. It is also recognised as a centre of excellence for sourcing and issuing secure national documents. Since 2012, Thales has supplied the DVLA with polycarbonate driving licences, a range of tachograph cards (for operations such as recording and storing the activity of commercial drivers), and residence cards for EU citizens to prove their right to live and work in the UK.
Key initiatives undertaken by Thales include adoption of eco-design principles throughout its identity card portfolio. For example, the size of the contactless microcontrollers embedded in the UK’s tachograph and residence cards has been halved, resulting in an equivalent reduction in CO2 microcontroller emissions while maintaining applications and security features unchanged.
In addition, Thales’ factories manufacturing the cards are accredited to the ISO 50001 standard, which focuses on energy efficiency. All these factories use 100% renewably electricity, accounting for over 70% of their total energy consumption. These improvements resulted in a reduction of over 80% of manufacturing related emissions (scope 1 and 2) since 2018.
For the remaining emissions of DVLA cards and on a yearly basis, Thales invests in high quality carbon offsetting programs with independently recognized carbon compensation organization such as Climate Impact Partners. For the DVLA contract, these include planting forests in the UK, restoring mangroves in Kenya, and distributing clean energy stoves in Bangladesh. In total, Thales has now offset 3,000 tonnes of CO2 emissions on behalf of the DVLA.
“Just like the DVLA, Thales is on the road to net zero and uses industry standard tools to calculate the Life Cycle Assessments of its products. This comprehensive calculator1 assesses the environmental impact of materials, packaging, transportation, document production and distribution, as well as end of life. Together with DVLA we are continually exploring new opportunities to improve the sustainability of the millions of cards supplied by Thales, looking for more responsible materials and solutions. At the same time, we remain focused on the need to maintain the security and integrity of identity credentials and deliver exceptional value for money for governments and public bodies” said Nathalie Gosset, Vice President Identity Document Solutions at Thales
1 This approach was developed with Quantis, a leading environmental sustainability consultancy, and is now supported by Solinnen, an expert consultancy specialising in Life Cycle Assessment, following recognised standards which consider the full life cycle of the products assessed and covers associated scope 1, 2 and 3.
About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity. It develops products and solutions that help make the world safer, greener and more inclusive. The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G. Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion. |
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604196678/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
